Fortune Alabi, MD
Critical Care Medicine · Kissimmee, FLNPI 1124025309
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $430,168 of the $587,333 with a category attached, or 73.2%. 60 manufacturers reported payments, led by AstraZeneca at 28.9% of the total. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,035 payments — averaging $288.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$170K
- Boehringer Ingelheim$111K
- Mallinckrodt Hospital Products Inc.$79K
- ANI Pharmaceuticals, Inc.$38K
- E.r. Squibb & Sons, L.L.C.$27K
- United Therapeutics Corporation$26K
- plus $136K from 54 others
Across 782 payments — averaging $3346.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$823K
- Insmed, Inc.$464K
- Boehringer Ingelheim$456K
- GSK$364K
- AstraZeneca$139K
- Roche Products Limited$131K
- plus $239K from 6 others
What the payments were for
- Consulting fees$61,15910%
- Speaking & faculty fees$430,16873%
- Travel & lodging$32,8726%
- Food & beverage$62,16311%
- Education$9300%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$587,333 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 75 | $971,372 |
| OpsumitMacitentan | 54 | $678,156 |
| UptraviSelexipag | 23 | $638,959 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 711 | $622,438 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 27 | $256,480 |
| AdempasRiociguat | 17 | $234,208 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 42 | $209,949 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 13 | $198,241 |
| Dupixent PenDupilumab | 40 | $190,664 |
| NuzyraOmadacycline Tosylate | 11 | $162,383 |
| NucalaMepolizumab | 40 | $151,312 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 143 | $142,552 |
| Breo ElliptaFluticasone/Vilanterol | 212 | $116,948 |
| Spiriva RespimatTiotropium Bromide | 88 | $77,033 |
| SymbicortBudesonide/Formoterol Fumarate | 208 | $68,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $7,713 | $1,317,11477 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $111,000 | $1,078,344211 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $24,566 | $960,7721,103 claims |
| BayerAdempas | $648 | $234,20817 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $169,991 | $217,599362 claims |
| Insmed, Inc.Arikayce | $15,377 | $198,24113 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $410 | $162,38311 claims |
| PfizerEliquis | $6,886 | $51,29663 claims |
| MerckDulera | $260 | $14,81423 claims |
| Hikma Pharmaceuticals USAEpinephrine | $17 | $4,07919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Kissimmee
- Fred UmehKissimmee$371K
- Maximo LamaKissimmee$255K
- Irtza SharifKissimmee$24K
- Arelis Cordero-GomezKissimmee$19K
- Nelson Medina VillanuevaKissimmee$15K
- James LucioKissimmee$7K
- Miguel Angel Ortiz-BonillaKissimmee$7K
- Louis GuzziOrlando$635K
- Debabrata BandyopadhyayTampa$398K
- Amit TandonWesley Chapel$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.